Aggressive vs nonaggressive therapy for metastatic NSCLC

Chest

Volumn 109, Issue 5 SUPPL., 1996, Pages 87S-92S

  Thatcher, Nicholas ^a   Niven, Robert M ^a   Anderson, Heather ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DOSE RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; PATIENT ATTITUDE; PHYSICAL PERFORMANCE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0029915216     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.109.5_Supplement.87S     Document Type: Article

References (52)

1. Raby B, Pater J, Mackillop WJ. A survey of Canadian physicians's beliefs about the use of radiation and chemotherapy in non-small cell lung cancer [abstract 1079]. Proc Am Soc Clin Oncol 1994; 13:327
2. Mackillop WJ, O'Sullivan B, Ward GK. Non-small cell lung cancer: how oncologists want to be treated. Int J Radiat Oncol Biol Phys 1987; 13:929-34
3. Slevin M, Mossman J, Bowling A, et al. Volunteers or victims: patients' views of randomised cancer clinical trials. Br J Cancer 1995; 71:1270-74
4. Slevin ML, Stubbs L, Plant HJ, et al. Attitude to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. BMJ 1990; 300:1458-60
5. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group Experience. J Clin Oncol 1991; 9:1618-26
6. Anderson H, Betticher DC, Ranson M, et al. Symptomatic benefit from chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumor related symptoms. Eur J Cancer (in press)
7. Bakker W, Van Oosterom AT, Aaronson NK, et al. Vindesine, cisplatin and bleomycin combination chemotherapy in non-small cell lung cancer: survival and quality of life. Eur J Cancer Clin Oncol 1986; 22:963-70
8. Poplin E, Baker L. Response rates - an evolution. Cancer Chemother Phannacol 1994; 34:361-63
9. Cormier Y, Bergeron D, La Forge J, et al. Benefits of polychemotherapy in advanced non-small cell bronchogenic carcinoma. Cancer 1982; 50:845-49
10. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-41
11. Ganz PA, Figlin RA, Haskell CM, et al. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer: does chemotherapy make a difference? Cancer 1989; 63:1271-78
12. Woods RL, Williams CJ, Levi J, et al. A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990; 61:608-11
13. Buccheri G, Ferrigno D, Rosso A, et al. Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer. Lung Cancer 1990; 6:87-98
14. Kaasa S, Lund E, Thorud E, et al. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 1991; 67:2443-47
15. Cellerino R, Tummarello D, Guidi F, et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer. J Clin Oncol 1991; 9:1453-61
16. Quoix E, Dietemann A, Charbonneau J, et al. La chimiotherapie comportant due cisplatine - est elle utile dans le cancer bronchique non microcellulaire au stade IV?: resultats d'un etude randomisee. Bull Cancer 1991; 78:341-46
17. Leung WT, Shiu WCT, Pang JCK, et al. Combined chemotherapy and radiotherapy versus best supportive care in the treatment of inoperable non-small cell lung cancer. Oncology 1992; 49: 321-26
18. Cartei G, Cartei F, Cantone A, et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small cell lung cancer. J Natl Cancer Inst 1993; 85:794-800
19. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342:19-21
20. Stewart LA, Pignon JP, Parmar MKB, et al. A meta-analysis using individual patient data from randomised clinical trials (RCTS) of chemotherapy (CT) in non-small cell lung cancer (NSCLC): III. Survival in the supportive care (SC) setting [abstract 1118]. Proc Am Soc Clin Oncol 1994; 13:337
21. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7:1602-13
22. Le Chevalier TL, Brisgand D, Douillard JY, et al. Randomised study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12:360-67
23. Giaccone G, Splinter T, Festen J, et al. Cisplatin (DDP) combined with teniposide (VM26) improves response and survival over VM26 alone in non-small cell lung cancer (NSCLC): a randomized trial of the EORTC Lung Cancer Cooperative Group [abstract 1102]. Proc Am Soc Clin Oncol 1993; 12:331
24. Davis S, Pandya MR, Rambotti P. Single-agent and combination chemotherapy for extensive non-small cell carcinomas of the lung. Cancer Treat Rep 1980; 64:685-88
25. Elliott JA, Ahmedzai S, Hole D, et al. Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur J Cancer Clin Oncol 1984; 20:1025-32
26. Einhorn LH, Loehrer PJ, Williams SD, et al. Random prospective study of vindesine versus vindesine plus high dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small cell lung cancer. J Clin Oncol 1986; 4:1037-43
27. Sorenson JB, Hansen HH, Dombernowsky P, et al. Chemotherapy for adenocarcinoma of the lung (WHO III): a randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs. J Clin Oncol 1987; 5:1169-77
28. Kubota K, Nakai R, Ogawara M, et al. A randomized study of cisplatin (DDP) versus DDP plus vindesine (VDS) in advanced non-small cell lung cancer (NSCLC), with an analysis of prognostic factors using multivariate methods [abstract 6.2.31]. Lung Cancer 1988; 4(suppl):A125
29. Klastersky J, Sculier JP, Bureau G, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1989; 7:1087-92
30. Rosso R, Salvalti F, Ardizzoni A, et al. Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer: results of prospective randomized FONICAP trial. Cancer 1990; 66:130-34
31. Crino L, Tonato M, Darwish S, et al. A randomized trial of three cisplatin-containing regimens in advanced non-small cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 1990; 26:52-6
32. Luedke DW, Einhorn L, Omura GA, et al. Randomized comparison of two combination regimens versus minimal chemotherapy in non-small cell lung cancer: a Southeastern Cancer Group Trial. J Clin Oncol 1990; 8:886-91
33. Vokes EE, Lyss AP, Herndon JE, et al. Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B. Ann Oncol 1992; 3:727-32
34. Veeder MH, Jett JR, Su JQ, et al. A phase III trial of mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer 1992; 70:2281-87
35. Bang YJ, Lee KH, Kang WK, et al. A prospective randomized study of cisplatin alone vs PEV (cisplatin, etoposid, vinblastine) chemotherapy in advanced non-small cell lung cancer [abstract 1167]. Proc Am Soc Clin Oncol 1993; 12:347
36. Depierre A, Chastang CL, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomised trial. Ann Oncol 1994; 5:37-42
37. Thatcher N, Anderson H, Smith DB, et al. Ifosfamide by bolus as treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 1986; 18(suppl 2):30-3
38. Thatcher N, Smith DB, Lind MJ, et al. Double alkylating agent therapy with ifosfamide and cyclophosphamide for advanced non-small cell lung cancer. Cancer 1988; 61:14-8
39. Cullen MH, Joshi R, Chetiyawardana AD, et al. Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 1988; 58:359-61
40. Kris MG, Gralla RH, Potanovich LM, et al. Assessment of pretreatment symptoms and improvement after EDAM+mitomycin+vinblastine (EMV) in patients (PTS) with inoperable non-small cell lung cancer (NSCLC) [abstract 883]. Proc Am Soc Clin Oncol 1990; 9:229
41. Gurney H, de Campos ES, Dodwell D, et al. Ifosfamide and mitomycin in combination for treatment of patients with progressive advanced non-small cell lung cancer. Eur J Cancer 1991; 27:565-68
42. Von Rohr A, Anderson H, McIntosh R, et al. Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer. Eur J Cancer 1991; 27:1106-08
43. Medical Research Council by its Lung Cancer Working Party. Inoperable non-small cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer 1991; 63:265-70
44. Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1994; 12:1821-26
45. Anderson H, Thatcher N, Walling J, et al. Gemcitabine and palliation of symptoms in non-small cell lung cancer [abstract 1238]. Proc Am Soc Clin Oncol 1994; 13:367
46. Thatcher N, Ranson M, Anderson H. Chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumor related symptoms. In: Aapro M, ed. Innovative antimetabolites in solid tumors: European School Oncology Monographs. Berlin: Springer, 1994; 47-53
47. Osoba D, Rusthoven JJ, Turnbull KA, et al. Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small cell lung cancer. J Clin Oncol 1985; 3:1478-85
48. Hardy JR, Noble T, Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer 1989; 60:764-66
49. Fernandez C, Rosell R, Abad-Esteve A, et al. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol 1989; 28:29-33
50. Cullen MH. The MIC regimen in non-small cell lung cancer. Lung Cancer 1993; 9(suppl 2):81-9
51. Kaasa S, Mastekaasa A, Naess S. Quality of life of lung cancer patients in a randomized clinical trial evaluated by a psychological well-being questionnaire. Acta Oncol 1988; 27:335-42
52. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85:365-76